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Guidelines and Guidance
I
n April 2006, the National Institute of Allergy and 
Infectious Disease (NIAID)-funded HIV Vaccine Trials 
Network and the NIAID Division of AIDS sponsored a 
workshop at which nonhuman primate (NHP) researchers 
and clinical trial scientists with HIV vaccine research expertise 
discussed how to more effectively use NHPs for evaluating 
HIV-1 vaccine candidates. This workshop precipitated a 
broad discussion on what types of NHP studies should be 
targeted in the critical preclinical pathway for HIV-1 vaccine 
candidates, especially those designed to elicit HIV-1-specific 
T cell responses. This paper describes the two-stage NHP 
screening strategy for T cell–based HIV-1 vaccines that 
emerged from discussions among the authors during the past 
year and a half. While conceived prior to the recent release 
of results for the phase IIB trial (STEP Study) of the Merck 
replication-incompetent adenovirus serotype 5 (Ad5)-HIV 
gag/pol/nef vaccine, we think the approach outlined below 
will be particularly useful for preclinical evaluation of vaccine 
candidates in the current vaccine pipeline for two reasons. 
First, the proposed strategy will eliminate suboptimal vaccine 
candidates early in the testing process (i.e., before initiation 
of phase I clinical trials). Second, the strategy would provide 
comparative immune response data in NHPs and humans 
for each promising HIV-1 vaccine product, information that 
could help the design of future vaccine candidates.
The most rigorous approach to judging the potential 
efficacy of HIV-1 vaccine candidates in NHP models is to 
determine if prototype vaccine candidates can protect the 
animals from the uncontrolled replication of a virulent 
challenge virus that recapitulates the pathogenic effects of 
HIV-1 in humans. At present, the most extensively studied 
HIV-1 vaccines are intended primarily to induce T cell 
immunity. While binding antibodies are reliably detected, 
if neutralizing antibodies are detected they are usually of 
low titer and narrow in their breadth. The primary expected 
outcome for T cell vaccines is the control of viral replication 
after experimental challenge with simian immunodeficiency 
virus (SIV) in NHPs or natural infection with HIV-1 in 
humans. This control should result in reduced viral load 
in plasma or tissue and preservation of CD4+ T cell counts, 
thereby preventing or delaying progression to AIDS. Progress 
toward developing an AIDS vaccine has been hampered by 
the lack of clarity about what host immune responses are 
required to prevent HIV-1 transmission or protect against 
disease progression. An immune correlate of HIV-1 vaccine-
mediated protection can only be identified after analysis 
of the results from one or more efficacy trials of effective 
vaccine(s). There are clear examples of vaccines that are 
capable of providing modest control of viral replication 
after SIV challenge of macaques. No single immune effector 
function, however, has been consistently associated with these 
vaccine-mediated effects. Thus, at present, protection against 
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disease progression in NHP studies is the best surrogate 
measure of vaccine efficacy that can be used in preclinical 
assessments of vaccine approaches. 
An assumption that underlies the current approach to 
HIV-1 vaccine testing has been that vaccine immunogenicity 
is an essential surrogate measure of vaccine efficacy but, 
as noted above, the validity of this assumption is unknown. 
Some HIV-1 vaccine candidates have moved into phase I 
clinical testing with positive immune responses in NHPs, 
but without challenge data (Figure 1). Others have been 
tested only in rodents, whose immune responses have not 
reliably predicted either the consistency or level of immune 
responses in people. Overall, many HIV-1 vaccine candidates 
that are immunogenic in animals have elicited only weak 
and/or transient immune responses in humans. Critically, 
only a very few vaccine candidates have demonstrated any 
efficacy in NHP challenge models using pathogenic SIV 
isolates, the model that best recapitulates the key features of 
HIV-1 infection and pathogenesis according to the following 
criteria: (1) persistent, progressive systemic infection after 
experimental inoculation; (2) use of the CCR5 coreceptor; 
(3) acute depletion of memory CD4+T cells, especially from 
mucosal sites; and (4) establishment of an initially disease-
free plateau phase in the majority of animals, followed by (5) 
progression to AIDS over a period of several months to years. 
The key requirements, relevance, and limitations of specific 
NHP models for evaluating HIV-1 vaccine candidates have 
recently been reviewed in detail [1–10].
It is important to recognize that, in the past, there has 
been a reluctance to give NHP models any “gatekeeper” 
status in the HIV-1 vaccine testing pathway, out of concern 
that potentially effective HIV-1 vaccine candidates might 
thereby be missed. Specific concerns include the imperfect 
(albeit close) recapitulation by the SIV-infected macaque 
model of HIV-1 infection of humans, and the possibility that 
some experimental challenges used in NHP models might 
be more stringent than is relevant for typical transmissions 
of HIV-1 between humans. The last few years, however, have 
seen the development of vaccines that are more consistently 
immunogenic in NHPs. Hence, identifying immunogens with 
increased immunogenicity and screening out those vaccine 
candidates likely to have low efficacy has now become a much 
higher priority element of the preclinical HIV-1 vaccine 
evaluation process. The cost and the regulatory requirements 
associated with the manufacture of vaccines for human 
clinical trials are additional factors; specifically, the number 
of HIV-1 vaccine candidates now available for phase I testing 
has increased, resulting in the need to develop cost-effective 
strategies to filter the vaccine pipeline. Thus, the role of NHP 
models in the process of selecting HIV-1 vaccines for clinical 
trials is now being reconsidered.
Shared Vision and Goals for Expediting HIV-1 Vaccine 
Development
There is a clear consensus that we must expedite the process 
of moving HIV-1 vaccine candidates from preclinical to 
clinical studies, using the most scientifically rigorous, 
efficient, and cost-effective strategies available. Furthermore, 
stringent criteria are needed to identify the HIV-1 vaccine 
candidates most likely to lead to a safe and effective vaccine 
product. To accomplish these shared goals, we strongly 
recommend identifying and implementing a strategy that 
places standardized, coordinated NHP studies in a central 
role in the preclinical evaluation of HIV-1 vaccines. Moreover, 
we recommend that HIV-1 vaccine candidates now advancing 
in the clinical pipeline also be evaluated by this NHP strategy 
to provide essential comparative data; determining which 
NHP studies should be conducted for each product currently 
in clinical trials should be done on a case-by-case basis. Our 
consensus proposal is a two-pronged strategy for evaluation 
of candidate vaccines in NHPs, using biologically based, 
clinically relevant endpoints to define go/no-go decision 
points prior to entry into phase I clinical trials (Figure 2).
The first phase of the proposed evaluation strategy for 
cytotoxic T lymphocyte–based vaccines would use the 
effectiveness of viral replication control following virulent SIV 
challenge of NHPs vaccinated with a prototype SIV vaccine as 
the primary criterion (Step 1 in Figure 2) for continuing the 
development of the vaccine candidate. Further testing would 
proceed only if the prototype vaccine showed consistent and 
statistically significant reduction of viremia compared with 
control animals. Given the diversity in HIV-1 sequences, 
there will almost certainly be greater divergence between 
vaccine and challenge virus sequences in the clinical setting 
than occurs in SIV challenge studies, so NHP studies may 
overestimate vaccine effectiveness. Conversely, the failure to 
demonstrate a degree of effectiveness in SIV challenge studies 
using closely matched vaccine and challenge sequences would 
argue strongly against the clinical efficacy of the vaccine 
approach in humans. The ability of the candidate vaccine to 
contain viral replication should be followed for six to eight 
months; longer periods of containment would constitute an 
additional important, but not definitive, evaluation criterion. 
This approach proposes that a specific HIV-1 vaccine 
candidate whose SIV prototype vaccine did not provide 
protection against SIV challenge should not proceed further 
in the developmental pathway. 
In retrospect, the proposed approach outlined in Figure 
2 predicts the lack of efficacy observed for the Merck Ad5 
gag/pol/nef HIV-1 vaccine in a human clinical trial. Studies 
published in 2002 showed that an SIV gag version of the 
Merck Ad5 HIV-1 gag vaccine was strongly immunogenic 
doi:10.1371/journal.pmed.0050173.g001
Figure 1. Current Preclinical Testing Strategy for Candidate HIV-1 
Vaccines
A variety of approaches are used to evaluate the immunogenicity of 
a specific candidate HIV-1 vaccine, X. These approaches may or may 
not include testing immunogenicity of the HIV-1 vaccine itself in non-
primates (e.g., rodents, rabbits, guinea pigs, etc.) or NHPs. In addition, 
the immunogenicity of an SIV or SHIV analogue of the HIV-1 vaccine may 
be tested in NHPs; this is done before NHP efficacy trials, which require 
challenge of NHPs with SIV or SHIV. Currently, neither immunogenicity 
nor challenge studies in NHPs are required preclinical assessments for 
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in macaques and protected the animals from uncontrolled 
replication of simian/human immunodeficiency virus (SHIV) 
89.6P [11]. SHIV 89.6P, however, is a virus that uses CXCR4 
as its dominant coreceptor, not the CCR5 coreceptor used 
by incident HIV-1 isolates, and the disease course that SHIV 
89.6P induces differs markedly from what occurs during most 
human infections with HIV-1 [2]. Thus, challenge of rhesus 
macaques with SHIV 89.6P, considered by some vaccinologists 
to be a predictive NHP challenge model five years ago, has 
been shown by the STEP Study results to be an inadequate 
predictor of subsequent human efficacy trials.
Studies published after the human trials of the HIV-1 
vaccine were underway demonstrated that the SIV version of 
the Merck Ad5 gag-only vaccine was not effective in reducing 
postinfection viremia of vaccinated rhesus macaques after 
SIVmac239 challenge; furthermore, an SIV gag DNA prime 
plus Ad5 SIV gag vaccine was only effective at reducing 
postinfection viral load in macaques with a specific major 
histocompatibility complex (MHC) class I allele, Mamu 
A*01, which is associated with an SIV cytotoxic T lymphocyte 
epitope that exhibits strong control of SIV replication in 
both vaccinated and control macaques [12]. Very recently, a 
DNA prime plus Ad5 SIV gag/tat/rev/nef vaccine was shown 
to be effective at reducing postinfection viral load in Mamu
A*01+ macaques challenged with SIVmac239 [13], but this 
vaccine has not yet been evaluated in macaques that do not 
have the Mamu A*01 allele. The above NHP vaccine studies 
used a homologous challenge virus; it is possible that less 
robust protection would be observed using a challenge 
virus less well matched to the vaccine construct, a scenario 
that would more closely mimic human exposures to HIV-1. 
For example, in macaques immunized with live-attenuated 
SIV, reduced control of viremia is observed after challenge 
with heterologous (SIVsmE660) compared to homologous 
(SIVmac239) virus [14].
Taken together, these recent NHP results suggest that 
candidate HIV-1 vaccines should be tested in NHPs with a 
range of MHC-1 haplotypes, excluding (or not solely relying 
on) animals with MHC alleles associated with an increased 
capacity to control viral replication, even in the absence 
of immunization, such as Mamu A*01, Mamu B*17, and 
Mamu B*08. The results also suggest that reduction of viral 
load in challenge models employing pathogenic, CXCR4-
using SHIVs, which represent a less stringent challenge 
than pathogenic R5 SIV isolates [2,8], appears not to be 
an effective model for predicting the clinical efficacy of T 
cell–based HIV-1 vaccine candidates. Overall, the outcomes 
from NHP studies of the SIV versions of the Merck Ad5-based 
HIV-1 vaccine provide support for modifying the way in 
which NHPs are used in preclinical HIV-1 vaccine research, 
as outlined above and summarized in Figure 2. For any 
promising HIV-1 vaccine candidate that demonstrates efficacy 
in NHPs against challenge with an SIV isolate containing 
envelope (or other antigens) homologous to the vaccine, 
challenge with an SIV isolate containing heterologous 
envelope could then be performed. Whether heterologous 
NHP challenge models can accurately predict HIV-1 vaccine 
efficacy will require further clinical testing.
It is important that the initial phase in the screening 
strategy uses a measure for efficacy that is consistent with the 
desired clinical endpoint. Using the ability to control viremia 
after SIV challenge as the endpoint for the initial screening 
step of candidate HIV-1 vaccines intended to induce T cell 
immunity is cost-effective and resource-efficient for three 
reasons. First, the immune responses required for any vaccine 
against HIV-1 or SIV to be effective are currently unknown. 
Second, the demonstration that a vaccine is effective against 
viral replication is a more direct and relevant criterion than 
its immunogenicity when selecting an HIV-1 vaccine for 
clinical evaluation, because the immune responses associated 
with vaccine protection are not known. There are more SIV 
doi:10.1371/journal.pmed.0050173.g002
Figure 2. Proposed Strategy for the Effective Use of NHPs in 
Preclinical Testing of Candidate HIV-1 T Cell–Based Vaccines
This strategy would be required for advancing an HIV-1 vaccine 
candidate to human testing. 
Step 1. A NHP challenge trial to evaluate the potential efficacy of each 
candidate HIV-1 vaccine would be required. The NHP challenge study 
must include three elements: an SIV analogue of the candidate HIV-1 
vaccine, an appropriate pathogenic SIV challenge isolate, and use of 
NHPs with diverse MHC class I haplotypes. Specific characteristics of SIV 
isolates that should be used in NHP challenge studies to evaluate efficacy 
of SIV vaccine analogues are described in the text. Pathogenic R5 SHIVs 
that recapitulate the key features of HIV-1 infection might be appropriate 
challenge viruses to estimate the ability of a neutralizing antibody-based 
HIV-1 vaccine candidate to prevent infection in NHPs. NHPs with diverse 
MHC class I haplotypes must be used to minimize selection of animals 
with strong natural capacity to control SIV replication even without 
vaccination.
Step 2. NHP immunogenicity testing of a candidate HIV-1 vaccine 
would only be undertaken if statistically significant protection from 
uncontrolled SIV replication were observed for vaccinated compared to 
unvaccinated NHPs in Step 1. Importantly, the immunogenicity of the 
HIV-1 vaccine product from a seed stock intended for clinical trials must 
be tested in NHPs. If strong, consistent immunogenicity of the candidate 
HIV-1 vaccine is observed in NHPs in Step 2, preclinical testing of toxicity 
and stability would proceed. 
Step 3. If a candidate HIV-1 vaccine is found to be immunogenic in NHPs, 
nontoxic, and stable, then the vaccine product would be made using 
GMP procedures, vialed, and released for phase I trials in humans.PLoS Medicine  |  www.plosmedicine.org 1203 August 2008  |  Volume 5  |  Issue 8  |  e173
vaccines that elicit moderate to robust SIV-specific immune 
responses, as measured by interferon-gamma enzyme-linked 
immunosorbent spot or cytokine flow cytometry assays, but 
that do not protect NHPs against SIV challenge, than there 
are SIV vaccines that do protect against challenge. Third, it is 
most cost-effective to eliminate candidate vaccines before they 
undergo good manufacturing practices (GMP) manufacture 
and evaluation in human clinical trials. 
One area of HIV-1 vaccine research that needs 
consideration is developing NHP models to define whether 
a vaccine candidate might increase HIV-1 acquisition. A 
provocative aspect of the STEP Study results is the increased 
rate of acquisition seen among men with neutralizing 
antibodies against Ad5 prior to vaccination or men who were 
uncircumcised when they entered the trial [15]. Availability 
of a NHP model to define the potential mechanisms for such 
findings could be a valuable tool in preclinical testing of 
candidate HIV-1 vaccines.
To facilitate the comparative evaluation of efficacy of 
various vaccine candidates, the design of the challenge 
studies should be standardized as much as possible, at least 
when similar classes of vaccine candidate are being evaluated 
(e.g., DNA vaccines, recombinant adenovirus vector-based 
vaccines). Relevant factors that should be standardized 
include the SIV vaccine insert isolate, SIV challenge virus, 
challenge route, challenge dose, endpoint measurements, 
and the macaque species. Specimens from NHP challenge 
studies should be evaluated for immunogenicity, both 
to evaluate potential immune correlates of control of 
viral replication and to link the results to subsequent 
immunogenicity studies conducted in macaques using 
corresponding vaccine products with HIV-1 inserts, including 
products manufactured under GMP conditions (see below).
The second phase in the proposed NHP-based HIV-1 
vaccine screening strategy would be to determine if an 
HIV-1 vaccine product from the clinical grade seed stock is 
sufficiently immunogenic in NHPs to warrant advancement 
into human trials (Step 2 in Figure 2). The rationale for 
this step is that the HIV-1 vaccine should be tested for 
immunogenicity in NHPs to avoid the costs of manufacturing 
and testing defective or low immunogenicity products in 
humans. To avoid delays in clinical development, NHP 
immunogenicity trials could be conducted either with a 
vaccine product derived from the seed stock to be used 
for human clinical trials, or from the GMP lot itself. The 
immunization regimen tested in the NHPs should represent 
the one to be evaluated in the proposed clinical trial. 
Similarly, when immunogenicity is evaluated in NHP models, 
validated T cell assays similar to those used in human trials 
should be used. The availability of central testing laboratories 
would facilitate the standardized testing of defined T cell 
responses in NHP vaccination studies, and thereby help 
obtain robust data for comparing immune responses in NHPs 
and humans. 
As outlined in Figure 2, a phase I clinical trial would 
be undertaken only if the product proved to be safe, 
immunogenic, and effective when tested in recommended, 
standardized NHP models. The immune responses elicited 
in NHPs by the HIV-1 vaccine should not be grossly different 
than those elicited by the SIV prototype. Further development 
of promising HIV-1 vaccine candidates that fail the 
immunogenicity-testing step might still be warranted if the 
manufacturing process had created an inactive product for a 
reason that was remediable. An added value of evaluating an 
HIV-1 vaccine product in NHPs and humans is the ability to 
compare immune responses more directly in these species, an 
ability that will be critical in the iterative process of improving 
future HIV-1 vaccine products. However, allowances will need 
to be made for certain vaccine types for which the human 
vaccines are not well suited for immunogenicity evaluation in 
NHPs; examples include peptide vaccines that are designed 
using epitopes recognized by human MHC alleles and vaccine 
vectors that do not replicate in NHPs.
Finally, there is consensus that conducting immunogenicity 
trials of multiple HIV-1 T cell vaccine candidates in NHPs, 
solely to establish a “rank order” for selecting candidates for 
evaluation in phase I clinical trials, may not be the best use 
of NHP resources; as noted above, it is not yet known what 
immune responses correlate with vaccine efficacy. Whether
the use of comparative immunogenicity studies in NHPs that 
are intended to rank and reject various iterations of a specific 
candidate vaccine prior to entry into phase I trials is an 
effective strategy is at present unclear. 
The most effective use of NHPs for predicting the clinical 
effectiveness of neutralizing antibody-based HIV-1 vaccines 
is unclear. Although vaccine-induced HIV-1-neutralizing 
antibodies of a sufficient titer can provide potent protection 
of NHPs against a single homologous challenge virus, 
neutralizing antibodies will need to be broadly cross-reactive 
to protect against the multiple HIV-1 genetic variants in 
the human population. When HIV-1 immunogens that 
elicit broadly neutralizing antibodies in primates become 
available, standardized in vitro assessments of vaccine-elicited 
neutralizing antibody responses, as measured against a 
wide spectrum of HIV-1 variants, may provide important 
information that complements the outcome of NHP 
challenge studies. 
In summary, we believe that it is time for the HIV vaccine 
field to consider a more standardized and rigorous approach 
to the preclinical testing of candidate HIV-1 vaccines. It is our 
opinion that the strategy proposed here is the best approach 
among currently available options.  
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